Guidelines on the Management of Latent Tuberculosis Infection. (Record no. 45306)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 05144nam a22004333i 4500 |
| 001 - CONTROL NUMBER | |
| control field | EBC1910127 |
| 003 - CONTROL NUMBER IDENTIFIER | |
| control field | MiAaPQ |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20240729123323.0 |
| 006 - FIXED-LENGTH DATA ELEMENTS--ADDITIONAL MATERIAL CHARACTERISTICS | |
| fixed length control field | m o d | |
| 007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION | |
| fixed length control field | cr cnu|||||||| |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 240724s2015 xx o ||||0 eng d |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| International Standard Book Number | 9789240693524 |
| Qualifying information | (electronic bk.) |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| Canceled/invalid ISBN | 9789241548908 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (MiAaPQ)EBC1910127 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (Au-PeEL)EBL1910127 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (OCoLC)899158487 |
| 040 ## - CATALOGING SOURCE | |
| Original cataloging agency | MiAaPQ |
| Language of cataloging | eng |
| Description conventions | rda |
| -- | pn |
| Transcribing agency | MiAaPQ |
| Modifying agency | MiAaPQ |
| 050 #4 - LIBRARY OF CONGRESS CALL NUMBER | |
| Classification number | RA644.T7 W675 2015 |
| 082 0# - DEWEY DECIMAL CLASSIFICATION NUMBER | |
| Classification number | 614.542 |
| 100 1# - MAIN ENTRY--PERSONAL NAME | |
| Personal name | WHO. |
| 245 10 - TITLE STATEMENT | |
| Title | Guidelines on the Management of Latent Tuberculosis Infection. |
| 250 ## - EDITION STATEMENT | |
| Edition statement | 1st ed. |
| 264 #1 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Place of production, publication, distribution, manufacture | Geneva : |
| Name of producer, publisher, distributor, manufacturer | World Health Organization, |
| Date of production, publication, distribution, manufacture, or copyright notice | 2015. |
| 264 #4 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Date of production, publication, distribution, manufacture, or copyright notice | ©2015. |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | 1 online resource (38 pages) |
| 336 ## - CONTENT TYPE | |
| Content type term | text |
| Content type code | txt |
| Source | rdacontent |
| 337 ## - MEDIA TYPE | |
| Media type term | computer |
| Media type code | c |
| Source | rdamedia |
| 338 ## - CARRIER TYPE | |
| Carrier type term | online resource |
| Carrier type code | cr |
| Source | rdacarrier |
| 505 0# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | Cover -- Contents -- Acknowledgements -- Abbreviations -- Declaration and management of conflict of interest -- Executive summary -- 1. Background and process -- 1.1. Background -- 1.2. Scope of the guidelines -- 1.3. Target audience -- 1.4. Development of the guidelines -- 1.5. Quality of evidence and strength of the recommendations -- 2. Recommendations -- 2.1. Identification of at-risk populations for LTBI testing and treatment -- 2.1.1. Summary of the evidence -- 2.1.2. Balance of benefits and harms -- 2.1.3. Values and preferences of clients and health-care providers -- 2.1.4. Resource considerations -- 2.2. Algorithm to test and treat LTBI -- 2.2.1. Summary of the evidence -- 2.2.2. Balance of benefits and harms -- 2.2.3. Values and preferences of clients and health-care providers -- 2.2.4. Resource considerations -- 2.3. Treatment options for LTBI -- 2.3.1. Summary of the evidence -- 2.3.2. Balance of benefits and harms -- 2.3.3. Values and preferences of clients and health-care providers -- 2.3.4. Resource considerations -- 2.4. Preventive treatment for contacts of MDR-TB cases -- 2.4.1. Summary of the evidence -- 2.4.2 Balance of benefits and harms -- 2.4.3. Values and preferences of clients and health-care providers -- 2.4.4. Resource considerations -- 2.4.5. Conclusions -- 3. Issues in Implementation -- 3.1. Adverse events monitoring -- 3.2. Risk of drug resistance following LTBI treatment -- 3.3. Adherence and completion of preventive treatment -- 3.4. Ethical considerations -- 3.5. Cost effectiveness -- 3.6. Programme management, monitoring and evaluation -- 4. Research gaps -- 4.1. Risk of progression to active TB disease and differential impact by population risk group -- 4.2. Defining the best algorithm to test and treat LTBI -- 4.3. Treatment options for LTBI and adverse event monitoring. |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | 4.4. Risk of drug resistance following LTBI treatment -- 4.5. Adherence and completion of treatment -- 4.6. Cost-effectiveness studies -- 4.7. Preventive treatment for MDR-TB contacts -- 4.8. Programme management -- 5. References -- 6. Annexes -- Annex 1: List of primary target countries for the guidelines -- Annex 2: List of systematic reviews conducted -- Annex 3: Recommended drug dosage. |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | Latent tuberculosis infection (LTBI) is defined as a state of persistent immune response to stimulation by Mycobacterium tuberculosis antigens without evidence of clinically manifested active TB. A direct measurement tool for M. tuberculosis infection in humans is currently unavailable. The vast majority of infected persons have no signs or symptoms of TB but are at risk for developing activetuberculosis (TB) disease. This can be averted by preventive treatment. These Guidelines on the management of latent tuberculosis infection were developed in accordanceto the requirements and recommended process of the WHO Guideline Review Committee andprovide public health approach guidance on evidence-based practices for testing treating andmanaging LTBI in infected individuals with the highest likelihood of progression to active disease.The guidelines are also intended to provide the basis and rationale for the development of nationalguidelines. The guidelines are primarily targeted at high-income or upper middle-income countrieswith an estimated TB incidence rate of less than 100 per 100 000 population. Resource-limited andother middle-income countries that do not belong to the above category should implement theexisting WHO guidelines on people living with HIV and child contacts below 5 years of age. |
| 588 ## - SOURCE OF DESCRIPTION NOTE | |
| Source of description note | Description based on publisher supplied metadata and other sources. |
| 590 ## - LOCAL NOTE (RLIN) | |
| Local note | Electronic reproduction. Ann Arbor, Michigan : ProQuest Ebook Central, 2024. Available via World Wide Web. Access may be limited to ProQuest Ebook Central affiliated libraries. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Tuberculosis-Prevention. |
| 655 #4 - INDEX TERM--GENRE/FORM | |
| Genre/form data or focus term | Electronic books. |
| 776 08 - ADDITIONAL PHYSICAL FORM ENTRY | |
| Relationship information | Print version: |
| Main entry heading | WHO |
| Title | Guidelines on the Management of Latent Tuberculosis Infection |
| Place, publisher, and date of publication | Geneva : World Health Organization,c2015 |
| International Standard Book Number | 9789241548908 |
| 797 2# - LOCAL ADDED ENTRY--CORPORATE NAME (RLIN) | |
| Corporate name or jurisdiction name as entry element | ProQuest (Firm) |
| 856 40 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://ebookcentral.proquest.com/lib/orpp/detail.action?docID=1910127">https://ebookcentral.proquest.com/lib/orpp/detail.action?docID=1910127</a> |
| Public note | Click to View |
No items available.